Q: Your team was the first to show it’s possible to extract T cells from a patient, multiply them to the billions in the lab, and infuse them back into the patient to seek and destroy particular diseased cells. What is the significance of this...
Q: In your roles as Assistant Vice Chancellor and Chief Information Officer of UCLA Health Sciences, you are responsible for the health information technology strategic plan. What emerging healthcare technologies do you anticipate will have the greatest impact on the strategic plan in the next...
Q: Immunotherapy is redefining how we treat cancer. How is this treatment approach impacting healthcare and in particular individualized medicine? A: Over the last couple of decades, we have been able to improve oncology treatment for late stage cancer patients. We have been able to...
Q: Genomics, Digital Health, Big Data, and Artificial Intelligence are some of the newest technologies/fields that are reshaping medicine and healthcare. • How will these technologies impact healthcare, and in particular individualized medicine? • What can we realistically expect from these technologies to improve healthcare and in what...
Q: Cardiovascular disease, listed as the underlying cause of death, accounts for about 1 in 3 deaths in the US with coronary heart disease being the leading cause (43.8%), followed by stroke (16.8%), and heart failure (9.0%). To address this issue, it is necessary to...
Q: Nanopore technology has been touted as a convenient and versatile DNA detection platform, but it has yet to reach its potential. Why is that, and how is your platform different? A: Single solid-state nanopore technology has yet to reach its potential even though the initial...
Q: You recently raised $4.1 million in seed funding from Andreessen Horowitz and Felicis Ventures. What differentiates Genesis Therapeutics from the over 200 AI/ML drug development startups in this space? A: Genesis is unique in its groundbreaking deep learning technology, its synergy of machine learning (ML)...
Q: Success rates of clinical trials have not improved over the years despite the advances in biomedical knowledge. How can recent advances in artificial intelligence be used to improve trials success rates A: It is evident that we are not learning sufficiently from the many clinical...
Q: What is your responsibility when selecting and/or working with these early stage companies? A: NCI SBIR Program Directors do not play a role in reviewing the SBIR/STTR applications. That process is done at the NIH Peer Review panel....
Q: There are various new, emerging therapeutics that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we...
